Recent Research Analysts’ Ratings Changes for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 10/27/2025 – Jazz Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $204.00 to $199.00. They now have an “overweight” rating on the stock.
• 10/24/2025 – Jazz Pharmaceuticals was given a new $183.00 price target on by analysts at Morgan Stanley.
• 10/22/2025 – Jazz Pharmaceuticals was given a new $170.00 price target on by analysts at Wells Fargo & Company.
• 10/20/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $167.00 to $180.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Jazz Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Jazz Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/24/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $163.00 to $167.00. They now have an “overweight” rating on the stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the transaction, the director directly owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 11,500 shares of company stock worth $1,525,280 over the last three months. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.